FinVector
↗Kuopio, Finland
FinVector is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) specializing in the research, development, and cGMP manufacturing of viral-based gene therapy products. Founded in 1993, the company has established itself as a pioneer in the field, leveraging advanced suspension and adherent-based platforms to support clinical and commercial supply.
Headquartered in Kuopio, Finland, FinVector operates state-of-the-art manufacturing facilities, including the recently opened 'Finport' facility, which is among the largest and most modern of its kind globally. The company is a subsidiary of Ferring Ventures S/A and plays a critical role in the manufacturing of Adstiladrin® (nadofaragene firadenovec-vncg), an FDA-approved gene therapy for bladder cancer.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Founded:1993
Ownership:subsidiary
Status:operating
FUNDING
Total Raised:$48.6M
Investors:Business Finland
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Gene therapy, Viral vectors (Adenovirus, AAV, Lentivirus)
Active Trials:0
Trial Phases:-
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Parent Company:Ferring Ventures S/A
Acquired By:Ferring Ventures S/A (2014-01-01)
Key Partnerships:Ferring Pharmaceuticals (Owner and primary client for Adstiladrin manufacturing), University of Eastern Finland (Academic research collaboration)
COMPETITION
Position:Leader
Competitors:Spark Therapeutics, Sana Biotechnology, Ultragenyx, Oxford Biomedica, Lonza
LEADERSHIP
Key Executives:
Matthias Krieger - Managing Director
Scientific Founders:Professor Seppo Ylä-Herttuala
LINKS
Website:finvector.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of FinVector and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with FinVector. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.